PET/CT, MRI play bigger roles in breast, prostate cancer

December 10, 2015

With the ability to accurately detect extraskeletal disease, PET/CT and whole-body MRI can change treatment plans for high-risk breast and prostate cancer patients, according to a study published in the December issue of the Journal of Nuclear Medicine.

Stanford University researchers also found the combined administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan achieves significantly greater sensitivity and accuracy than alternative methods for the detection of skeletal lesions.

Read the full article.